Pdcd-1L1 Activators
Pdcd-1L1 activators encompass a diverse range of compounds that, while not directly targeting Pdcd-1L1, have the potential to modulate its activity through intricate signaling pathways. These pathways play critical roles in the regulation of cellular responses, immune functions, and T cell activities. The identified compounds impact various key signaling pathways, including the MAPK, AMPK, PI3K/Akt, JNK, NF-κB, mTOR, HDAC3, and Pim kinase pathways. For instance, SB-203580, a p38 MAPK inhibitor, can potentially influence Pdcd-1L1 activation by modulating the MAPK signaling pathway, which is intricately involved in cellular responses and immune function regulation. Similarly, A769662, an AMPK activator, may impact Pdcd-1L1 through the AMPK signaling pathway, crucial for cellular energy homeostasis and immune response modulation. These compounds offer potential avenues for indirect modulation of Pdcd-1L1 activity by influencing pathways intricately linked to immune responses.
Wortmannin, a PI3K inhibitor, and Rapamycin, an mTOR inhibitor, present additional candidates for indirect Pdcd-1L1 modulation. The PI3K/Akt pathway, regulated by Wortmannin, is fundamental for immune response modulation and T cell functions, while mTOR, targeted by Rapamycin, plays a crucial role in regulating immune responses and T cell activities. These compounds exemplify the intricate interplay between cellular signaling pathways and the potential for modulating Pdcd-1L1 indirectly. Furthermore, compounds like BAY 11-7082, an NF-κB inhibitor, and SP600125, a JNK inhibitor, showcase additional pathways influencing Pdcd-1L1. NF-κB is a central regulator of immune responses, and JNK is implicated in apoptosis and cellular stress responses, suggesting potential connections with Pdcd-1L1 regulation. The diverse array of identified compounds collectively highlights the multifaceted nature of Pdcd-1L1 activators, each offering a unique perspective on potential indirect modulation through intricate cellular signaling networks.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580 is a p38 MAPK inhibitor that affects the MAPK signaling pathway. By inhibiting p38 MAPK, this compound can potentially modulate Pdcd-1L1 activation, as the MAPK pathway is intricately involved in the regulation of cellular responses and immune function. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662 is an AMP-activated protein kinase (AMPK) activator. By directly activating AMPK, this compound may influence Pdcd-1L1 activation, as AMPK is involved in cellular energy homeostasis and immune response regulation, presenting a potential pathway for modulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor, affecting the PI3K/Akt pathway. By inhibiting PI3K, this compound can potentially impact Pdcd-1L1 activation, as the PI3K/Akt pathway plays a role in immune response regulation and modulation of T cell functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK (c-Jun N-terminal kinase) inhibitor, influencing the JNK signaling pathway. By inhibiting JNK, this compound may potentially modulate Pdcd-1L1 activation, as the JNK pathway is implicated in the regulation of apoptosis, immune responses, and cellular stress. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-κB, impacting the NF-κB signaling pathway. By inhibiting NF-κB, this compound can potentially influence Pdcd-1L1 activation, as NF-κB is a key regulator of immune responses and plays a role in the modulation of T cell functions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR (mechanistic target of rapamycin) inhibitor, affecting the mTOR signaling pathway. By inhibiting mTOR, this compound can potentially modulate Pdcd-1L1 activation, as the mTOR pathway is involved in the regulation of immune responses and T cell functions. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509 is a histone deacetylase 3 (HDAC3) inhibitor, influencing the epigenetic regulation of gene expression. By modulating HDAC3, this compound may potentially impact Pdcd-1L1 activation, as epigenetic regulation is intricately linked to immune response modulation and T cell functions. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
AZD6244 is a MEK inhibitor affecting the MAPK/ERK pathway. By inhibiting MEK, this compound can potentially modulate Pdcd-1L1 activation, as the MAPK/ERK pathway is intricately involved in the regulation of cellular responses and immune function. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
PF-4708671 is an AMPK inhibitor, affecting the AMPK signaling pathway. By inhibiting AMPK, this compound may potentially modulate Pdcd-1L1 activation, as AMPK is involved in cellular energy homeostasis and immune response regulation, presenting a potential pathway for modulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, affecting the PI3K/Akt pathway. By inhibiting PI3K, this compound can potentially modulate Pdcd-1L1 activation, as the PI3K/Akt pathway plays a role in immune response regulation and modulation of T cell functions. | ||||||